Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone for Heart Failure in Congenital Heart Disease
NCT01069510Phase 2Completed
- Sponsor
- Oregon Health & Science University
- Start
- Feb 2010
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of spironolactone in heart failure (HF), Endomyocardial fibrosis (EMF), sponsored by Oregon Health & Science University. Started Feb 2010; status: completed.
02
Drugs
spironolactone
03
Conditions
heart failure (HF)Endomyocardial fibrosis (EMF)
Beyond the preview
Go deeper on NCT01069510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01069510.